uniQure (QURE) Stock Forecast & Price Target

uniQure is viewed favorably because its lead Huntington’s disease asset, AMT-130, now has a clearer regulatory path after FDA alignment on using 3-year data for a BLA and potentially avoiding a sham-surgery control, which materially lowers development risk. The company also has commercial and clinical upside from a large HD opportunity, with about 100k carriers, 40k symptomatic, 20k diagnosed and roughly 6k eligible on day one, while management sees pricing comparable to other hospital-administered gene therapies and a broader multi-therapy market similar to SMA. Beyond HD, uniQure’s credibility is reinforced by HEMGENIX being the first gene therapy approved for Hemophilia B, plus promising pipeline momentum in mTLE, Fabry and cardiovascular programs, supporting a high-upside platform thesis.

uniQure is weighed down by a highly uncertain clinical-stage profile, where value depends on programs like AMT-130, AMT-260, AMT-162, and AMT-191 while HEMGENIX commercialization remains vulnerable to launch delays, reimbursement risk, and long-term pricing pressure. The company also faces regulatory uncertainty, intellectual property risk, competition from PFE, IONS, and WVE, plus the possibility of safety signals or failure to show sustained efficacy in trials, any of which could undermine pipeline value. Although the stated framework implies a total firm value of approximately $5.5 billion using a 12% discount rate and a 6.0x terminal multiple, the need to assign success probabilities and model revenue builds in the 2030s highlights how dependent the investment case remains on distant, uncertain execution.